FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2462014591> ?p ?o ?g. }

• W2462014591 endingPage "72977" @default.
• W2462014591 startingPage "72961" @default.
• W2462014591 abstract "// Asma Beldi-Ferchiou 1, 2, 11 , Marion Lambert 1, 2 , Stéphanie Dogniaux 3 , Frédéric Vély 4, 5 , Eric Vivier 4, 5 , Daniel Olive 6 , Stéphanie Dupuy 1 , Frank Levasseur 1 , David Zucman 7 , Céleste Lebbé 8 , Damien Sène 1, 2, 9 , Claire Hivroz 4 , Sophie Caillat-Zucman 1, 2, 10 1 Institut National de Recherche Médicale (INSERM) UMR1149, Centre de Recherche Sur l’Inflammation, Équipe Immunité Innée Chez l’enfant, Hôpital Robert Debré, Paris, France 2 Université Paris Diderot, Sorbonne Paris Cité, Paris, France 3 Institut Curie, Centre de Recherche, PSL Research University, INSERM U932 Immunité et Cancer, Paris, France 4 Centre d’Immunologie de Marseille-Luminy, Aix-Marseille Université UM2, INSERM U1104, CNRS UMR7280, Marseille, France 5 Immunologie, Hôpital de la Conception, Assistance Publique- Hôpitaux de Marseille, Marseille, France 6 Centre de Cancérologie de Marseille, INSERM U1068, Equipe Immunité et Cancer, Institut Paoli-Calmettes, Aix-Marseille Université, CNRS, UMR7258, Marseille, France 7 Hôpital Foch, Service de Médecine Interne, Suresnes, France 8 Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Département de Dermatologie, INSERM U976, Université Paris Diderot, Paris, France 9 Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Lariboisière, Département de Médecine Interne, Paris, France 10 Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Laboratoire d’Immunologie, Paris, France 11 Present address: Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Henri Mondor, Laboratoire d’Immunologie, Créteil, France Correspondence to: Sophie Caillat-Zucman, email: sophie.caillat@inserm.fr Keywords: NK cells, Kaposi sarcoma, PD-1, immune checkpoint, tumor escape Received: March 31, 2016      Accepted: September 13, 2016      Published: September 20, 2016 ABSTRACT Programmed Death-1 (PD-1), an inhibitory receptor expressed by activated lymphocytes, is involved in regulating T- and B-cell responses. PD-1 and its ligands are exploited by a variety of cancers to facilitate tumor escape through PD-1-mediated functional exhaustion of effector T cells. Here, we report that PD-1 is upregulated on Natural Killer (NK) cells from patients with Kaposi sarcoma (KS). PD-1 was expressed in a sub-population of activated, mature CD56 dim CD16 pos NK cells with otherwise normal expression of NK surface receptors. PD-1 pos NK cells from KS patients were hyporesponsive ex vivo following direct triggering of NKp30, NKp46 or CD16 activating receptors, or short stimulation with NK cell targets. PD-1 pos NK cells failed to degranulate and release IFNγ, but exogenous IL-2 or IL-15 restored this defect. That PD-1 contributed to NK cell functional impairment and was not simply a marker of dysfunctional NK cells was confirmed in PD-1-transduced NKL cells. In vitro , PD-1 was induced at the surface of healthy control NK cells upon prolonged contact with cells expressing activating ligands, i.e. a condition mimicking persistent stimulation by tumor cells. Thus, PD-1 appears to plays a critical role in mediating NK cell exhaustion. The existence of this negative checkpoint fine-tuning NK activation highlights the possibility that manipulation of the PD-1 pathway may be a strategy for circumventing tumor escape not only from the T cell-, but also the NK-cell mediated immune surveillance." @default.
• W2462014591 created "2016-07-22" @default.
• W2462014591 creator A5002774188 @default.
• W2462014591 creator A5004581254 @default.
• W2462014591 creator A5009181226 @default.
• W2462014591 creator A5012617867 @default.
• W2462014591 creator A5015365788 @default.
• W2462014591 creator A5022372742 @default.
• W2462014591 creator A5023634131 @default.
• W2462014591 creator A5025478490 @default.
• W2462014591 creator A5029679351 @default.
• W2462014591 creator A5034845035 @default.
• W2462014591 creator A5043200001 @default.
• W2462014591 creator A5045510726 @default.
• W2462014591 creator A5058875000 @default.
• W2462014591 date "2016-09-20" @default.
• W2462014591 modified "2023-10-18" @default.
• W2462014591 title "PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma" @default.
• W2462014591 cites W1511635744 @default.
• W2462014591 cites W1521064197 @default.
• W2462014591 cites W1547920084 @default.
• W2462014591 cites W1562804387 @default.
• W2462014591 cites W1875845937 @default.
• W2462014591 cites W1964265426 @default.
• W2462014591 cites W1966280949 @default.
• W2462014591 cites W1971222772 @default.
• W2462014591 cites W1974308995 @default.
• W2462014591 cites W1978436252 @default.
• W2462014591 cites W1991650736 @default.
• W2462014591 cites W1996408493 @default.
• W2462014591 cites W1996875315 @default.
• W2462014591 cites W1996891899 @default.
• W2462014591 cites W1997241837 @default.
• W2462014591 cites W2004016007 @default.
• W2462014591 cites W2007267205 @default.
• W2462014591 cites W2013013791 @default.
• W2462014591 cites W2016789384 @default.
• W2462014591 cites W2022230965 @default.
• W2462014591 cites W2022580424 @default.
• W2462014591 cites W2039123767 @default.
• W2462014591 cites W2047849342 @default.
• W2462014591 cites W2047976284 @default.
• W2462014591 cites W2051890542 @default.
• W2462014591 cites W2055243308 @default.
• W2462014591 cites W2057499380 @default.
• W2462014591 cites W2063264144 @default.
• W2462014591 cites W2065202184 @default.
• W2462014591 cites W2065968597 @default.
• W2462014591 cites W2066002010 @default.
• W2462014591 cites W2074876842 @default.
• W2462014591 cites W2079439457 @default.
• W2462014591 cites W2081816766 @default.
• W2462014591 cites W2086397613 @default.
• W2462014591 cites W2089345792 @default.
• W2462014591 cites W2090872978 @default.
• W2462014591 cites W2096682838 @default.
• W2462014591 cites W2097514222 @default.
• W2462014591 cites W2099047660 @default.
• W2462014591 cites W2101653483 @default.
• W2462014591 cites W2106943429 @default.
• W2462014591 cites W2107556275 @default.
• W2462014591 cites W2107752337 @default.
• W2462014591 cites W2113606974 @default.
• W2462014591 cites W2115536507 @default.
• W2462014591 cites W2115935733 @default.
• W2462014591 cites W2118471749 @default.
• W2462014591 cites W2118982164 @default.
• W2462014591 cites W2119896120 @default.
• W2462014591 cites W2121158936 @default.
• W2462014591 cites W2127424425 @default.
• W2462014591 cites W2130506153 @default.
• W2462014591 cites W2130992177 @default.
• W2462014591 cites W2131640081 @default.
• W2462014591 cites W2140875987 @default.
• W2462014591 cites W2144720739 @default.
• W2462014591 cites W2144953100 @default.
• W2462014591 cites W2145871366 @default.
• W2462014591 cites W2147448501 @default.
• W2462014591 cites W2149748445 @default.
• W2462014591 cites W2152897456 @default.
• W2462014591 cites W2155464214 @default.
• W2462014591 cites W2156906256 @default.
• W2462014591 cites W2160834915 @default.
• W2462014591 cites W2162819607 @default.
• W2462014591 cites W2397739282 @default.
• W2462014591 cites W2560367415 @default.
• W2462014591 cites W2572174216 @default.
• W2462014591 doi "https://doi.org/10.18632/oncotarget.12150" @default.
• W2462014591 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5341956" @default.
• W2462014591 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27662664" @default.
• W2462014591 hasPublicationYear "2016" @default.
• W2462014591 type Work @default.
• W2462014591 sameAs 2462014591 @default.
• W2462014591 citedByCount "234" @default.
• W2462014591 countsByYear W24620145912017 @default.
• W2462014591 countsByYear W24620145912018 @default.
• W2462014591 countsByYear W24620145912019 @default.
• W2462014591 countsByYear W24620145912020 @default.

• next